Title:
APPLICATION OF PDE3A IN JUDGMENT OF TUMOR TREATMENT EFFECT OF ANAGRELID
Document Type and Number:
WIPO Patent Application WO/2017/186103
Kind Code:
A1
Abstract:
Application of a phosphodiesterase PDE3A and genes thereof in judgment of a tumor treatment effect of Anagrelide. Specifically provided is usage of a PDE3A gene sequence, protein, or anti-PDE3A protein specific antibody in preparation of a diagnostic reagent or a diagnostic kit. The diagnostic reagent or kit is used for (a) judging a tumor treatment effect of Anagrelide, and/or (b) judging whether Anagrelide is appropriate for treating a tumor patient. Also provided is a corresponding detection kit.
Inventors:
YU QIANG (CN)
LIU JUEYU (CN)
LIU JUEYU (CN)
Application Number:
PCT/CN2017/081908
Publication Date:
November 02, 2017
Filing Date:
April 25, 2017
Export Citation:
Assignee:
SHANGHAI INST MATERIA MEDICA CAS (CN)
International Classes:
G01N33/574; C12Q1/68; G01N33/68
Domestic Patent References:
| WO2017027854A1 | 2017-02-16 | |||
| WO2015055898A2 | 2015-04-23 |
Other References:
WALL, L. D. ET AL.: "Identification of cancer-cytotoxic modulators of PDE3A by predictive chemogenomics", NATURE CHEMICAL BIOLOGY, vol. 12, 14 December 2015 (2015-12-14), pages 102 - 107, XP055364721
Attorney, Agent or Firm:
XU & PARTNERS,LLC. (CN)
Download PDF:
Previous Patent: A THERAPEUTIC INHIBITOR FOR EBV-ASSOCIATED TUMOR WITH TAILOR RESPONSIVE OPTICAL IMAGING
Next Patent: PWM GENERATION CIRCUIT
Next Patent: PWM GENERATION CIRCUIT